All trials
NCT07367815PHASE1NOT YET RECRUITING

Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease

✨ Plain-English version on the way · ~2 days

We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:

A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
Read full record on ClinicalTrials.gov

Eligibility check — Phoenix members

Phoenix members see for THIS trial:

  • APOE genotype match
  • Cognitive status fits inclusion
  • Specific exclusions flagged
  • Distance to nearest site
Check my eligibility — become a member
Start
2026-03-01

Interventions tested

  • DRUGCellREADY® drug product IV dose of 50 millions
  • DRUGCellREADY® drug product IV dose of 100 millions
  • DIAGNOSTIC_TESTcerebral RMI
  • DIAGNOSTIC_TESTPET scan
View full record on ClinicalTrials.gov

We use cookies to enhance your experience.